Overview

Study Evaluating rhBMP-2/CPM in Closed Distal Radius Fractures

Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety of rhBMP-2/CPM administered to subjects presenting with closed distal radius fractures. The key safety variables comprising this assessment are: 1) incidence of delayed union; 2) median time to fracture union (assessed by the investigators); 3) incidence of local neurovascular events (those involving the region under study [RUS]); and 4) rate of fracture displacement. The primary objective will be met if these outcomes in the active and placebo treatment groups are at least comparable to those of the SOC control group.
Phase:
Phase 1
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer